vs
Side-by-side financial comparison of PERRIGO Co plc (PRGO) and UGI CORP (UGI). Click either name above to swap in a different company.
UGI CORP is the larger business by last-quarter revenue ($2.1B vs $1.1B, roughly 1.9× PERRIGO Co plc). UGI CORP runs the higher net margin — 14.4% vs -127.8%, a 142.2% gap on every dollar of revenue. On growth, UGI CORP posted the faster year-over-year revenue change (3.9% vs -2.5%). PERRIGO Co plc produced more free cash flow last quarter ($148.6M vs $-155.0M). Over the past eight quarters, PERRIGO Co plc's revenue compounded faster (1.3% CAGR vs -7.5%).
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
UGI Corporation is a natural gas and electric power distribution company headquartered in King of Prussia, Pennsylvania, with extensive operations in the United States and Europe.
PRGO vs UGI — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.1B | $2.1B |
| Net Profit | $-1.4B | $297.0M |
| Gross Margin | 32.6% | — |
| Operating Margin | -116.0% | 22.0% |
| Net Margin | -127.8% | 14.4% |
| Revenue YoY | -2.5% | 3.9% |
| Net Profit YoY | -3093.9% | -20.8% |
| EPS (diluted) | $-10.23 | $1.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.1B | $2.1B | ||
| Q3 25 | $1.0B | $1.2B | ||
| Q2 25 | $1.1B | $1.4B | ||
| Q1 25 | $1.0B | $2.6B | ||
| Q4 24 | $1.1B | $2.0B | ||
| Q3 24 | $1.1B | $1.2B | ||
| Q2 24 | $1.1B | $1.4B | ||
| Q1 24 | $1.1B | $2.4B |
| Q4 25 | $-1.4B | $297.0M | ||
| Q3 25 | $7.5M | $-13.0M | ||
| Q2 25 | $-8.4M | $-163.0M | ||
| Q1 25 | $-6.4M | $479.0M | ||
| Q4 24 | $-44.4M | $375.0M | ||
| Q3 24 | $-21.0M | $-273.0M | ||
| Q2 24 | $-108.4M | $-48.0M | ||
| Q1 24 | $2.0M | $496.0M |
| Q4 25 | 32.6% | — | ||
| Q3 25 | 36.1% | — | ||
| Q2 25 | 34.4% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 33.9% | — | ||
| Q3 24 | 37.2% | — | ||
| Q2 24 | 37.0% | — | ||
| Q1 24 | 33.1% | — |
| Q4 25 | -116.0% | 22.0% | ||
| Q3 25 | 7.0% | 1.1% | ||
| Q2 25 | 4.3% | -6.8% | ||
| Q1 25 | 4.5% | 26.6% | ||
| Q4 24 | 10.0% | 24.5% | ||
| Q3 24 | 7.4% | -20.4% | ||
| Q2 24 | -2.5% | 5.0% | ||
| Q1 24 | -5.1% | 29.7% |
| Q4 25 | -127.8% | 14.4% | ||
| Q3 25 | 0.7% | -1.1% | ||
| Q2 25 | -0.8% | -12.0% | ||
| Q1 25 | -0.6% | 18.2% | ||
| Q4 24 | -3.9% | 18.9% | ||
| Q3 24 | -1.9% | -22.6% | ||
| Q2 24 | -10.2% | -3.6% | ||
| Q1 24 | 0.2% | 20.6% |
| Q4 25 | $-10.23 | $1.34 | ||
| Q3 25 | $0.05 | $-0.08 | ||
| Q2 25 | $-0.06 | $-0.76 | ||
| Q1 25 | $-0.05 | $2.19 | ||
| Q4 24 | $-0.32 | $1.74 | ||
| Q3 24 | $-0.15 | $-1.26 | ||
| Q2 24 | $-0.79 | $-0.23 | ||
| Q1 24 | $0.01 | $2.30 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $251.0M |
| Total DebtLower is stronger | — | $6.0B |
| Stockholders' EquityBook value | $2.9B | $5.0B |
| Total Assets | $8.5B | $15.8B |
| Debt / EquityLower = less leverage | — | 1.19× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $251.0M | ||
| Q3 25 | $432.1M | $335.0M | ||
| Q2 25 | $454.2M | $350.0M | ||
| Q1 25 | $409.9M | $426.0M | ||
| Q4 24 | $558.8M | $240.0M | ||
| Q3 24 | $1.5B | $213.0M | ||
| Q2 24 | $542.8M | $183.0M | ||
| Q1 24 | $658.5M | $263.0M |
| Q4 25 | — | $6.0B | ||
| Q3 25 | — | $6.5B | ||
| Q2 25 | — | $5.7B | ||
| Q1 25 | — | $6.6B | ||
| Q4 24 | — | $6.6B | ||
| Q3 24 | — | $6.4B | ||
| Q2 24 | — | $6.3B | ||
| Q1 24 | — | $6.7B |
| Q4 25 | $2.9B | $5.0B | ||
| Q3 25 | $4.4B | $4.8B | ||
| Q2 25 | $4.5B | $4.9B | ||
| Q1 25 | $4.4B | $5.0B | ||
| Q4 24 | $4.3B | $4.6B | ||
| Q3 24 | $4.6B | $4.3B | ||
| Q2 24 | $4.5B | $4.7B | ||
| Q1 24 | $4.7B | $4.8B |
| Q4 25 | $8.5B | $15.8B | ||
| Q3 25 | $10.1B | $15.5B | ||
| Q2 25 | $10.1B | $15.4B | ||
| Q1 25 | $9.8B | $15.7B | ||
| Q4 24 | $9.6B | $15.4B | ||
| Q3 24 | $11.2B | $15.1B | ||
| Q2 24 | $10.4B | $15.1B | ||
| Q1 24 | $10.6B | $15.6B |
| Q4 25 | — | 1.19× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 1.17× | ||
| Q1 25 | — | 1.32× | ||
| Q4 24 | — | 1.44× | ||
| Q3 24 | — | 1.48× | ||
| Q2 24 | — | 1.34× | ||
| Q1 24 | — | 1.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $175.4M | $66.0M |
| Free Cash FlowOCF − Capex | $148.6M | $-155.0M |
| FCF MarginFCF / Revenue | 13.4% | -7.5% |
| Capex IntensityCapex / Revenue | 2.4% | 10.7% |
| Cash ConversionOCF / Net Profit | — | 0.22× |
| TTM Free Cash FlowTrailing 4 quarters | $145.1M | $282.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $175.4M | $66.0M | ||
| Q3 25 | $51.7M | $90.0M | ||
| Q2 25 | $75.9M | $289.0M | ||
| Q1 25 | $-64.5M | $684.0M | ||
| Q4 24 | $312.6M | $164.0M | ||
| Q3 24 | $42.2M | $151.0M | ||
| Q2 24 | $9.5M | $390.0M | ||
| Q1 24 | $-1.4M | $522.0M |
| Q4 25 | $148.6M | $-155.0M | ||
| Q3 25 | $29.8M | $-168.0M | ||
| Q2 25 | $56.7M | $67.0M | ||
| Q1 25 | $-90.0M | $538.0M | ||
| Q4 24 | $274.9M | $-47.0M | ||
| Q3 24 | $15.1M | $-115.0M | ||
| Q2 24 | $-18.9M | $185.0M | ||
| Q1 24 | $-26.5M | $353.0M |
| Q4 25 | 13.4% | -7.5% | ||
| Q3 25 | 2.9% | -14.4% | ||
| Q2 25 | 5.4% | 4.9% | ||
| Q1 25 | -8.6% | 20.4% | ||
| Q4 24 | 24.2% | -2.4% | ||
| Q3 24 | 1.4% | -9.5% | ||
| Q2 24 | -1.8% | 13.7% | ||
| Q1 24 | -2.4% | 14.6% |
| Q4 25 | 2.4% | 10.7% | ||
| Q3 25 | 2.1% | 22.1% | ||
| Q2 25 | 1.8% | 16.3% | ||
| Q1 25 | 2.4% | 5.5% | ||
| Q4 24 | 3.3% | 10.6% | ||
| Q3 24 | 2.5% | 22.0% | ||
| Q2 24 | 2.7% | 15.2% | ||
| Q1 24 | 2.3% | 7.0% |
| Q4 25 | — | 0.22× | ||
| Q3 25 | 6.89× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.43× | ||
| Q4 24 | — | 0.44× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -0.70× | 1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
UGI
Segment breakdown not available.
